← Back to Search

ABCS Training for Cardiovascular Risk in HIV/AIDS (ABCSinHIV Trial)

N/A
Waitlist Available
Led By Kevin Fiscella, MD, MPH
Research Sponsored by University of Rochester
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age 40-79 years
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 months
Awards & highlights

ABCSinHIV Trial Summary

This trial will develop and test strategies to increase the use of evidence-based interventions for heart disease among people living with HIV.

Who is the study for?
This trial is for HIV patients aged 40-79 at certain sites with a moderate risk of heart disease, who speak English or Spanish, and have texting capabilities. Clinicians treating these patients must be willing to try new strategies. Excluded are those with past heart events, vascular diseases, pregnancy, inability to consent, or involvement in another CVD trial.Check my eligibility
What is being tested?
The study tests the implementation of ABCS training (aspirin use, blood pressure control, cholesterol management, smoking cessation) to reduce cardiovascular risks in people living with HIV. It aims to improve the adoption of evidence-based interventions through this strategy.See study design
What are the potential side effects?
Since this trial focuses on implementing a training strategy rather than a medical intervention like medication or surgery, it does not directly involve side effects typically associated with clinical trials.

ABCSinHIV Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 40 and 79 years old.

ABCSinHIV Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
10-year CVD risk reduction

ABCSinHIV Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: TrainingExperimental Treatment1 Intervention
CVD risk after the patient and clinician training
Group II: ControlActive Control1 Intervention
CVD risk prior to the patient and clinician training

Find a Location

Who is running the clinical trial?

National Heart, Lung, and Blood Institute (NHLBI)NIH
3,847 Previous Clinical Trials
47,813,959 Total Patients Enrolled
University of RochesterLead Sponsor
845 Previous Clinical Trials
530,740 Total Patients Enrolled
Clinical Directors NetworkNETWORK
12 Previous Clinical Trials
9,969 Total Patients Enrolled

Media Library

ABCS training Clinical Trial Eligibility Overview. Trial Name: NCT03902431 — N/A
HIV/AIDS Research Study Groups: Control, Training
HIV/AIDS Clinical Trial 2023: ABCS training Highlights & Side Effects. Trial Name: NCT03902431 — N/A
ABCS training 2023 Treatment Timeline for Medical Study. Trial Name: NCT03902431 — N/A
~755 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top